Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria

Faculty	Medicine	Year:	2020
Type of Publication:	ZU Hosted	Pages:
Authors:
Journal:	Breast Care Karger	Volume:

Keywords :	Adjuvant Chemotherapy , Patients with Breast Cancer
Abstract:	-Oncotype DX assay recurrence score (ODX-RS) cut-off values have recently changed after the publication of the TAILOR-X trial results. We aim to explore decisions for adjuvant chemotherapy (ACT) based on physicians’ clinical assessment and the evolving ODX-RS. -Overtreatment and discrepancies in the management of patients with ER+/Her2–/LN– early BC can be minimized by the implementation of ODX genomic assay. Some differences in ACT recommendations exist between ODX-RS-1 and ODX-RS-2.

Author Related Publications

Rasha Mohamed Mostafa Hagag, "Impact of Prognostic Nutritional Index and Systemic Immune-Inflammation Index on the Clinical Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib", Zagazig University Medical Journal, 2022 More
Rasha Mohamed Mostafa Hagag, "Diagnosis of Sepsis among Adult Patients with AML Using Scd14", Ain Shams University, Faculty of Medicine, Pan Arab League of Continuous Medical Education, 2021 More
Rasha Mohamed Mostafa Hagag, "Prognostic Impact of microRNAs (miR-155, miR-10a, let-7a) on the Outcome of Adult Patients with Acute Myeloid Leukemia.", Zagazig University, Faculty of Medicine, 2021 More
Shereen Mostafa Saleh Elshorbagy, "Prognostic Roles of ZNF703 and SMAD4 Expression in Patients with Papillary Thyroid Cancer and Association with Nodal Metastasis", pubmed, 2022 More
Shereen Mostafa Saleh Elshorbagy, "RNA-binding proteins RBM-HuR, RBM3 and PODXL expression in urothelial carcinoma of the urinary bladder. Prognostic and clinical implications", PMID: 35079236, 2022 More